Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228930 · ClinicalTrials.gov registry record
Tamoxifen Pharmacogenetics and Clinical Effects
A clinical trial, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- 297
- Enrollment target
NCT00228930: Completed study, sponsored by National Institute of General Medical Sciences (NIGMS).
NCT00228930 is a clinical trial that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 297 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00228930 has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- 297 participants
- Enrollment target
Study Summary
The purpose of this research is to try to identify which women who take tamoxifen are likely to suffer from hot flashes or are more likely to have other side effects or benefits from the drug. The researchers will do so by determining whether there are mutations that normally occur in human DNA that might influence the way individuals respond to medications.
Interventions
- DRUG Tamoxifen (pharmacodynamic analysis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-08 |
What the finished NCT00228930 record still lists
NCT00228930 is an observational study that tracks outcomes without assigning an intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Tamoxifen (pharmacodynamic analysis) is the first listed.
NCT00228930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00228930 about?
NCT00228930 is a clinical study titled "Tamoxifen Pharmacogenetics and Clinical Effects". The purpose of this research is to try to identify which women who take tamoxifen are likely to suffer from hot flashes or are more likely to have other side effects or benefits from the drug. The researchers will do so by determining whether there are mutations that normally occur in human DNA that...
What is the current status of trial NCT00228930?
This trial is currently completed. The enrollment target is 297 participants. The study started on 2002-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00228930?
The interventions under investigation include: Tamoxifen (pharmacodynamic analysis) (DRUG).
Who is sponsoring clinical trial NCT00228930?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia